Loading...
Drug Pricing Investigation--Lost Savings: How Prohibiting Medicare Negotiation Has Cost Taxpayers
House Committee on Oversight and Reform
House Committee on Oversight and Reform
Abstract
The House Committee on Oversight and Reform investigated ten companies selling expensive prescription drugs to Medicare, revealing tactics that keep prices high.The report discloses billions in taxpayer losses due to Medicare's inability to directly negotiate lower drug prices and highlights drug companies targeting the U.S. for price increases. Despite over 47 million Americans enrolled in Medicare Part D plans, the Secretary of Health and Human Services is barred from direct negotiations and is constrained by federal requirements.
Date
2021-09-22
Document Type
House Staff Report
Serial Number
Document Length
26 pages
Congress
117
Relation
DOI
Keywords
Staff Reports
PAP Major Code
3: Health
PAP Minor Code
335: Prescription Drug Coverage and Costs